在当代队列中随机活检对多参数磁共振成像靶向前列腺活检的附加价值
本研究纳入1552例多参数磁共振成像(mpMRI)阳性并连续接受mpMRI靶向活检和系统随机超声引导活检(SBx)的患者,评估SBx的附加价值及过度诊断率。结果显示,mpMRI靶向活检和/或SBx对临床显著前列腺癌(csPCa)的检出率为753/1552(49%),SBx的附加价值为145/944(15%),SBx的过度诊断率为146/656(22%)。多变量分析显示,PI-RADS 4分索引病灶、PI-RADS 5分索引病灶和年龄与SBx附加价值独立相关。
要点
- mpMRI靶向活检和/或SBx对csPCa的检出率为49%(753/1552)。
- SBx的附加价值为15%(145/944),过度诊断率为22%(146/656)。
- PI-RADS 4分和5分索引病灶及年龄与SBx附加价值独立相关。
核心结论
- 在真实世界分析中,SBx对附加价值和过度诊断率有显著影响,亚组分析显示在任何评估的风险组中附加价值均无显著下降,因此作者不推荐省略与mpMRI引导前列腺活检同步进行的SBx。
研究设计与样本
- 研究纳入1552例mpMRI阳性并连续接受mpMRI靶向活检和SBx的患者,评估SBx的附加价值和过度诊断率。
主要发现
- mpMRI靶向活检和/或SBx对csPCa的检出率为753/1552(49%)。
- SBx的附加价值为145/944(15%)。
- SBx的过度诊断率为146/656(22%)。
- 比较既往前列腺活检患者与初次活检患者,SBx的附加价值无变化。
- 多变量分析中,PI-RADS 4分索引病灶(OR 3.19,95%CI 1.66-6.78;P=0.001)、PI-RADS 5分索引病灶(OR 2.89,95%CI 1.39-6.46;P=0.006)和年龄(OR 1.05,95%CI 1.03-1.08;P<0.001)与SBx附加价值独立相关。
临床怎么用
- 作者不推荐省略与mpMRI引导前列腺活检同步进行的SBx。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the added value of concurrent systematic randomised ultrasonography-guided biopsy (SBx) to multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy and the additional rate of overdiagnosis of clinically insignificant prostate cancer (ciPCa) by SBx in a large contemporary, real-world cohort. PATIENTS AND METHODS: A total of 1552 patients with positive mpMRI and consecutive mpMRI-targeted biopsy and SBx were enrolled. Added value and the rate of overdiagnosis by SBx was evaluated. PRIMARY OUTCOME: added value of SBx, defined as detection rate of clinically significant PCa (csPCa; International Society of Urological Pathology [ISUP] Grade ≥2) by SBx, while mpMRI-targeted biopsy was negative or showed ciPCa (ISUP Grade 1). SECONDARY OUTCOME: rate of overdiagnosis by SBx, defined as detection of ciPCa in patients with negative mpMRI-targeted biopsy and PSA level of <10 ng/mL. RESULTS: Detection rate of csPCa by mpMRI-targeted biopsy and/or SBx was 753/1552 (49%). Added value of SBx was 145/944 (15%). Rate of overdiagnosis by SBx was 146/656 (22%). Added value of SBx did not change when comparing patients with previous prostate biopsy and biopsy naïve patients. In multivariable analysis, a Prostate Imaging-Reporting and Data System (PI-RADS) 4 index lesion (odds ratio [OR] 3.19, 95% confidence interval [CI] 1.66-6.78; P = 0.001), a PI-RADS 5 index lesion (OR 2.89, 95% CI 1.39-6.46; P = 0.006) and age (OR 1.05, 95% CI 1.03-1.08; P < 0.001) were independently associated with added value of SBx. CONCLUSIONS: In our real-world analysis, we saw a significant impact on added value and added rate of overdiagnosis by SBx. Subgroup analysis showed no significant decrease of added value in any evaluated risk group. Therefore, we do not endorse omitting concurrent SBx to mpMRI-guided biopsy of the prostate.
引用
- Chaloupka M, Pyrgidis N, Ebner B, et al. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort. BJU Int. 2024. PMID: 38060339. doi:10.1111/bju.16248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。